Recruiting Atrial Fibrillation Studies in Atlanta
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet t...
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
This study is a phase 2 / 3 prospective, double-blind, randomized, multicenter, placebo-controlled study for prevention of acute GVHD (aGVHD) in participants undergoing an unrelated (matched or single...
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGV...
MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cel...
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the second...
A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with H...
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in...
About Atrial Fibrillation Clinical Trials in Atlanta
Atrial fibrillation (AFib) is the most common type of heart arrhythmia, causing an irregular and often rapid heartbeat. It significantly increases the risk of stroke, heart failure, and other complications. Treatment includes blood thinners, heart rate or rhythm control medications, and procedures like ablation.
There are currently 8 atrial fibrillation clinical trials recruiting participants in Atlanta, GEORGIA. These studies are seeking a combined 4,797 participants. Research is being sponsored by Icahn School of Medicine at Mount Sinai, Eli Lilly and Company, CSL Behring and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Atrial Fibrillation Clinical Trials in Atlanta — FAQ
Are there atrial fibrillation clinical trials in Atlanta?
Yes, there are 8 atrial fibrillation clinical trials currently recruiting in Atlanta, GEORGIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Atlanta?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.
Are clinical trials in Atlanta free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.
What atrial fibrillation treatments are being tested?
The 8 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for atrial fibrillation.
Data updated March 2, 2026 from ClinicalTrials.gov